In a randomized clinical trial, researchers assessed the effectiveness of umifenovir in combination with other drugs for the treatment of patients hospitalized with moderate to severe COVID-19.
In this meta-analysis of studies on COVID-19 and SARS, researchers compared the association between all-cause mortality and treatment with glucocorticoids.
Researchers conducted a multi-center, open-label, randomized controlled trial to compare the effects of enoxaparin at the standard prophylactic dose with the intermediate dose for the treatment of adult patients with severe COVID-19.
The researchers tested their hypothesis that a decrease in respiratory virus incidence would be associated with a reduction in inappropriate ambulatory antibiotic orders.
Researchers studied patients with pulmonary tuberculosis to better understand the impact of sex on mortality and sputum microbiological status after treatment initiation.
Researchers compared trends in antibiotic prescription rates during the period preceding the pneumococcal conjugate vaccine (PCV), as well as the early and late PCV periods, among Jewish vs Bedouin children.
Researchers conducted a phase 3 trial to ascertain whether treatment regimens including rifapentine with or without moxifloxacin can provide a lasting cure for drug-susceptible pulmonary tuberculosis in 4 months vs 6 months of standard therapy.
Researchers compared the antibody responses of 2 age groups, one younger than 60 years and one older than 80 years, to the first and second doses of the Pfizer-BioNTech COVID-19 vaccination.
A team of investigators sought to estimate the burden of acute respiratory illness in ambulatory care settings for 12 respiratory viruses in Washington state during the 2018-2019 influenza season.
Investigators conducted a systematic review and meta-analysis of 37 studies that used a test-negative design to evaluate IVE against influenza-associated hospitalization in children.
